Dendl, K.
Finck, R.
Giesel, F. L.
Kratochwil, C.
Lindner, T.
Mier, W.
Cardinale, J.
Kesch, C.
Röhrich, M.
Rathke, H.
Gampp, H.
Ristau, J.
Adeberg, S.
Jäger, D.
Debus, J.
Haberkorn, U.
Koerber, S. A.
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 23 March 2021
Accepted: 4 July 2021
First Online: 3 August 2021
Change Date: 15 August 2022
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: UH, TL, CK, WM, and FLG have a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine. UH, TL, CK, and FLG also have shares of a consultancy group for iTheranostics. FLG is a medical advisor for ABX Advanced Biochemical Compound, Telix Pharmaceuticals, and SOFIE Biosciences. JD reports grants from ViewRay Inc., grants from CRI The Clinical Research Institute GmbH, grants from Accuray International Sarl, grants from RaySearch Laboratories AB, grants from Vision RT Limited, grants from Merck Serono GmbH, grants from Astellas Pharma GmbH, grants from Astra Zeneca GmbH, grants from Siemens Healthcare GmbH, grants from Solution Akademie GmbH, grants from Ergomed PLC Surrey Research Park, grants from Quintiles GmbH, grants from Pharmaceutical Research Associates GmbH, grants from Boehringer Ingelheim Pharma GmbH & Co. KG, grants from PTW-Freiburg Dr. Pychlau GmbH, grants from Nanobiotix S.A, outside the submitted work. SAK reports grants from ViewRay Inc., outside the submitted work. SA received grants from Accuray International Sarl, Merck Serono GmbH, Astra Zeneca GmbH, MSD, and Novocure GmbH outside the submitted work. S.A. holds shares from Novocure GmbH, Actinium Pharmaceuticals, Chimerix Inc., Telix Pharmaceuticals, and Clovis Oncology. All other authors declare no potential conflicts of interest relevant to this article.